Nivolumab Plus Ipilimumab Better for Advanced RCC
Among intermediate- and poor-risk patients, the risk for death was 37% lower with nivolumab plus ipilimumab than with sunitinib.
Sitio Web patrocinado por:
Sitio Web patrocinado por:
Among intermediate- and poor-risk patients, the risk for death was 37% lower with nivolumab plus ipilimumab than with sunitinib.
Copyright © 2025, Sociedad Venezolana de Nefrología - RIF: J-30370247-3.
Diseñado por 